← Back to Search

Alkylating agents

Cisplatin for Breast Cancer

Q: What therapeutic purposes does Cisplatin commonly serve?

Cisplatin is an effective treatment against <a href="https://www.withpower.com/clinical-trials/lymphoma">lymphoma</a>, <a href="https://www.withpower.com/clinical-trials/acute-lymphoblastic-leukemia">acute lymphoblastic leukemia</a> (<a href="https://www.withpower.com/clinical-trials/all">ALL</a>), and <a href="https://www.withpower.com/clinical-trials/soft-tissue-sarcoma">soft tissue sarcoma</a> (STS).

Phase 2

Waitlist Available

Led By Nadine Tung, MD

Research Sponsored by Beth Israel Deaconess Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial is a Phase II study of cisplatin in patients with BRCA-mutated breast cancer.

Eligible Conditions

Breast Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Rate of Pathologic Complete Response (pCR)

Secondary outcome measures

Analysis of Pre-chemotherapy Biopsies

Clinical Response Rate

Number of Grade 3 and Grade 4 Adverse Events

+4 more

Trial Design

2Treatment groups

Active Control

Group I: CisplatinActive Control1 Intervention

Cisplatin q 3 wk x 4

Group II: Doxorubicin-CyclophosphamideActive Control2 Interventions

Doxorubicin q 2-3 wk x 4 Cyclophosphamide q 2-3 wk x 4

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Beth Israel Deaconess Medical CenterLead Sponsor

836 Previous Clinical Trials

13,010,116 Total Patients Enrolled

47 Trials studying Breast Cancer

7,147 Patients Enrolled for Breast Cancer

Nadine Tung, MDPrincipal InvestigatorBeth Israel Deaconess Medical Center

2 Previous Clinical Trials

414 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there severe side-effects associated with Cisplatin use?

"Cisplatin is a phase 2 drug, which means that while there is some evidence of its safety, none exists for its efficacy. Our team at Power rates Cisplatin's safety as a 2."

Answered by AI

Are there any other Cisplatin-based clinical trials worth mentioning?

"Cisplatin was first trialed in 1997 at Spectrum Health Hospital - Butterworth Campus. In the years since, there have been 2252 completed trials worldwide. As of now, 1634 clinical trials are ongoing; many of these located in Durham, North carolina."

Answered by AI

Could you inform me as to how many different hospitals are trialing this medication?

"Currently, this trial is looking for participants from 15 different locations. These sites are based in cities such as Durham, Boston and Hartford. To minimize travelling demands, it is recommended that you select a clinical site close to your location."

Answered by AI

What therapeutic purposes does Cisplatin commonly serve?

"Cisplatin is an effective treatment against lymphoma, acute lymphoblastic leukemia (ALL), and soft tissue sarcoma (STS)."

Answered by AI

Has there been a study like this one before?

"In total, there are 1634 active clinical trials worldwide for the use of Cisplatin. These studies began in 1997 and have since been completed in 2252 locations across 79 countries."

Answered by AI

Are we currently enrolling individuals in this clinical trial?

"No, this clinical trial is no longer recruiting patients. The study was first posted on October 1st 2012 and was most recently updated on May 9th 2022. However, if the reader is interested in other trials, there are 2698 studies for breast cancer and 1634 for Cisplatin that are currently looking for participants."

Answered by AI

Recent research and studies

brcaJournal

Neoadjuvant Cisplatin in brca Carriers with Her2‐negative Breast Cancer

Takamizawa, Shigemasa, Hiroto Ishiki, Tatsunori Shimoi, Masaki Shimizu, and Eriko Satomi. 2020. “Neoadjuvant Cisplatin in brca Carriers with Her2‐negative Breast Cancer”. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO). doi:10.1200/jco.20.00789.

Journal of Clinical OncologyJournal

Reply to S. Takamizawa Et Al

Tung, Nadine, Michele R. Hacker, and Judy E. Garber. 2020. “Reply to S. Takamizawa Et Al”. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO). doi:10.1200/jco.20.01190.

brcaJournal

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-cyclophosphamide in Germline brca Carriers with Her2-negative Breast Cancer (the INFORM Trial)

Tung, Nadine, Banu Arun, Michele R. Hacker, Erin Hofstatter, Deborah L. Toppmeyer, Steven J. Isakoff, Virginia Borges, et al.. 2020. “TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-cyclophosphamide in Germline brca Carriers with Her2-negative Breast Cancer (the INFORM Trial)”. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO). doi:10.1200/jco.19.03292.

clinicaltrials.govStudy